BIPP: A Complete Guide to the Biotechnology Industry Partnership Programme

Some biotech innovations are simply too ambitious, too capital intensive, or too high risk for any single company to carry alone, even well funded ones. Advanced therapeutics, novel vaccine platforms, and next generation diagnostic technologies often demand years of sustained investment before they reach the market, with no guarantee of success along the way. Left entirely to private capital, many of these high value, high risk innovations would never get built, even though their eventual impact, on public health, on national capability, could be enormous.

The Biotechnology Industry Partnership Programme (BIPP), approved by the Government of India in November 2008 and launched by the Biotechnology Industry Research Assistance Council (BIRAC) in early 2009, exists to share that risk. Structured as an advanced technology scheme, BIPP is deliberately built to cover the entire spectrum of product development, not just an early prototype stage, through a genuine risk sharing partnership between government and industry. Unlike more narrowly targeted early stage schemes, BIPP is open to companies of every size, from small biotech ventures to large, established players, provided the underlying innovation carries real national or social relevance.

The Funding Opportunity: What BIPP Actually Offers

• Support structure: BIPP offers varying models of grant in aid and or loan support, tailored to the nature and risk profile of each project. BIRAC's contribution can run up to 50 percent of the project cost as grant in aid, with the applicant company or LLP funding the remaining share.
• Categories of support: Category I covers products of high national and social relevance, supported through a combination of grant in aid and loan, with interest rates typically in the 2 to 3 percent range. Other categories address different risk and relevance profiles within the broader BIPP framework.
• Disbursement structure: grant in aid funds are typically released in five milestone linked installments, an initial 30 percent on signing the funding agreement, 20 percent each on completion of three technical milestones, and a final 10 percent on submission of the project completion report.
• Scale of funding: BIPP has historically supported large scale project costs, with cumulative scheme allocations running into hundreds of crores across its full portfolio of funded projects.
• Repayment structure: where a loan component is involved, repayment is typically structured over 10 equal half yearly installments. Where a grant component applies, the company pays BIRAC a royalty of 5 percent on annual net sales of the resulting product, an obligation that ends once cumulative royalty payments equal the grant in aid disbursed.
• IP ownership: intellectual property rights arising from BIPP funded projects are vested with the company, not with BIRAC or the government, a deliberate design choice to keep commercial incentives aligned with the innovating company.
• Application cycle: BIPP runs both regular calls for proposals and special or need based calls throughout the year, rather than being limited to fixed periodic windows.

Who is eligible

• Companies of any size. Small, medium, and large enterprises are all eligible under BIPP, unlike more early stage focused BIRAC schemes.
• Projects should address products of genuine national or social relevance, covering the full spectrum of product development rather than only the earliest research stage.
• Applicants are generally expected to have moved beyond pure proof of concept work into genuine product development, scale up, clinical validation, or regulatory stage activity.

How the process works

1. Monitor BIRAC's announcements for open BIPP calls, which may be regular cycles or special, need based calls issued throughout the year.
2. Prepare a detailed proposal outlining the project's technical scope, national or social relevance, and the specific category of support, grant, loan, or a combination, being sought.
3. Submit the proposal online through BIRAC's proposal submission system. Hard copy submissions are generally not accepted.
4. If approved, funding is disbursed according to the agreed grant or loan structure, with repayment, where applicable, following the scheme's standard installment or royalty terms.

Given BIPP's project specific and often larger scale nature, engaging with BIRAC early, even before a formal call opens, can help clarify which support category and structure best fits a given project.

Where BIPP Fits in the Broader BIRAC Ecosystem

BIPP sits at a distinctly more advanced, higher stakes point in the biotech funding journey than earlier stage schemes like BIG or SEED Fund. Where BIG helps validate an idea and SEED Fund helps a startup cross its first valley of death, BIPP is built for companies of any size tackling genuinely difficult, capital intensive product development challenges with real national significance. It is frequently mentioned alongside the Small Business Innovation Research Initiative (SBIRI) as one of BIRAC's two primary vehicles for supporting more mature, product stage biotech innovation, with BIPP generally addressing larger scale, higher risk, higher relevance projects.